Cheilanthifoline
Cheilanthifoline has anti-osteoclastogenic property, it gives significant inhibitions on receptor activator of nuclear factor-κB ligand-induced differentiation of mouse bone marrow-derived macrophages into multinucleated osteoclasts. Cheilanthifoline also shows promising in vitro antiplasmodial activities against Plasmodium falciparum.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J of Engineering Science&Technology2018, 13(9):2820-2828
Int J Mol Sci.2019, 20(23):E6071
Acta Edulis Fungi2020, 27(02):63-76.
Molecules.2021, 26(19):6032.
Evid Based Complement Alternat Med.2018, 2018:3610494
Nutrients2023, 15(18), 4016.
Food Bioscience2022, 50:102187.
J Pharmaceut Biomed2020, 178:112894
Applied Biological Chemistry2020, 63:37.
Mol Neurobiol.2021, 58(8):3665-3676.
Related and Featured Products
Arch Pharm Res. 2016 May;39(5):713-20.
Anti-osteoclastogenic effects of isoquinoline alkaloids from the rhizome extract of Sinomenium acutum.[Pubmed:
26992921 ]
METHODS AND RESULTS:
A phytochemical investigation for the rhizome extract from Sinomenium acutum (Menispermaceae) resulted in the isolation of several active principles responsible for the anti-osteoclastogenic property of the extract, together with related isoquinoline alkaloids (1-13) including two new compounds, 1 and 2. Among isolated compounds, salutaridine (7), dauricumine (10), Cheilanthifoline (12), and dauriporphine (13) were observed to give significant inhibitions on receptor activator of nuclear factor-κB ligand-induced differentiation of mouse bone marrow-derived macrophages into multinucleated osteoclasts, respectively.
CONCLUSIONS:
The chemical structures of two newly isolated compounds, 1 and 2 were established as 8-demethoxycephatonine (1) and 7(R)-7,8-dihydrosinomenine (2), by spectroscopic analyses including 2D NMR experiments.
Phytother Res. 2010 Apr;24(4):481-5.
Antiplasmodial agents from the Bhutanese medicinal plant Corydalis calliantha.[Pubmed:
19496064 ]
The alkaloidal components of the Bhutanese medicinal plant Corydalis calliantha Long, which is used for the treatment of malaria, have been assessed.
METHODS AND RESULTS:
Four known alkaloids, protopine (1), scoulerine (2), Cheilanthifoline (3) and stylopine (4) are reported from this plant for the first time. The protopine alkaloid, protopine, and the tetrahydroprotoberine alkaloid, Cheilanthifoline, showed promising in vitro antiplasmodial activities against Plasmodium falciparum, both wild type (TM4) and multidrug resistant (K1) strains with IC(50) values in the range of 2.78-4.29 microM. Such activity had not been demonstrated previously for Cheilanthifoline.
CONCLUSIONS:
The results thus support, at a molecular level, the clinical use of this plant in the Bhutanese traditional medicine and identified Cheilanthifoline as a potential new antimalarial drug lead.
